Brown Rudnick Advises on $72-million Series B Financing for Werewolf Therapeutics Inc.
PUBLISHED ON: 01/28/2021
Brown Rudnick advised RA Capital Management on the Werewolf Therapeutics Inc. $72-million Series B financing to advance a novel class of cancer biotherapeutics. Werewolf is an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments designed to focus the body's immune response to selectively target cancer.
The financing was led by RA Capital Management and joined by new investors Deerfield Management, HBM Healthcare Investments, Soleus Capital, Adage Capital, Sphera Healthcare, and CaaS Capital. Also participating in the financing were Werewolf's Series A investors including MPM Capital, Longwood Fund, Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises, and DC Investment Partners. The transaction accelerates Werewolf's pipeline of systemically delivered, conditionally activated INDUKINE™ molecules into clinical stage development and supports efforts to build a leading immuno-oncology drug discovery and development team. RA Capital Management is a leading investment manager dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, and diagnostics.